Haleon plc (LON:HLN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
382.10
-0.10 (-0.03%)
Mar 26, 2025, 5:21 PM BST
Market Cap 34.52B
Revenue (ttm) 11.23B
Net Income (ttm) 1.44B
Shares Out 9.04B
EPS (ttm) 0.16
PE Ratio 24.34
Forward PE 20.12
Dividend 0.07 (1.73%)
Ex-Dividend Date Apr 24, 2025
Volume 20,830,348
Average Volume 33,782,661
Open 381.80
Previous Close 382.20
Day's Range 378.70 - 383.10
52-Week Range 319.20 - 417.70
Beta 0.23
RSI 41.63
Earnings Date Feb 27, 2025

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprisi... [Read more]

Sector Healthcare
Founded 1715
Employees 25,408
Stock Exchange London Stock Exchange
Ticker Symbol HLN
Full Company Profile

Financial Performance

In 2024, Haleon's revenue was 11.23 billion, a decrease of -0.61% compared to the previous year's 11.30 billion. Earnings were 1.44 billion, an increase of 37.46%.

Financial Statements

News

Sensodyne toothpaste maker Haleon now an independent company after Pfizer sells stake

Shares in the consumer health group - originally a joint venture between Pfizer and GSK - are up nearly a fifth since it joined the stock market in 2022.

7 days ago - This is Money

Pfizer offloads final shares in Sensodyne maker Haleon

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.

7 days ago - Evening Standard

Pfizer Sells Remaining Stake in Haleon for $3.25 Billion

Pfizer Sells Remaining Stake in Haleon for $3.25 Billion

7 days ago - GuruFocus

Pfizer sells entire Haleon stake for $3.24 billion

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for t...

7 days ago - Reuters

Pfizer to sell remaining stake in Haleon

8 days ago - Seeking Alpha

Pfizer to dispose of entire Haleon stake

Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.

8 days ago - Reuters

2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs

Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, wit...

21 days ago - Seeking Alpha

Haleon: Growing Profits And Dividend

Haleon's dividend grew 10% and is well-covered by FCF, but the 1.6% yield is less attractive compared to peers. See why I rate HLN stock a hold.

21 days ago - Seeking Alpha

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025

London-based consumer healthcare group Haleon Plc (NYSE: HLN) stock is trading lower on Thursday. Haleon, GSK Plc’s (NYSE: GSK) spun off, reported revenue of 11.23 billion pounds (US$14.19 billion) ...

27 days ago - Benzinga

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025

London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.

27 days ago - Benzinga

Haleon CEO: We're relatively low-exposed to tariffs

Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results

27 days ago - CNBC International TV

Haleon CEO: We're relatively low-exposed to tariffs

Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results

27 days ago - CNBC

Haleon Expects Further Growth After Profit Rises

27 days ago - The Wall Street Journal

Earnings Scheduled For February 27, 2025

Companies Reporting Before The Bell • Hafnia (NYSE: HAFN) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ: ARGX) is projected to report quarterly earnings at $1.06 per share...

27 days ago - Benzinga

Haleon to invest $54 mln in US R&D centre to boost product innovation

Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovation...

2 months ago - Reuters

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

On Thursday, Dr. Reddy's Laboratories Ltd (NYSE: RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginall...

2 months ago - Benzinga

Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%

Pfizer Sells $700M Stake in Haleon, Trimming Ownership to 7.3%

2 months ago - GuruFocus

Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%

Pfizer Sells Stake in Haleon, Reduces Holding to 7.3%

2 months ago - GuruFocus

Pfizer Sells Stake in Haleon for $3.05 Billion

Pfizer Sells Stake in Haleon for $3.05 Billion

2 months ago - GuruFocus